Stopping controversial asthma drugs could have downside: study

August 27, 2012 by Randy Dotinga, Healthday Reporter in Immunology

Stopping controversial asthma drugs could have downside: study

Findings differ from FDA caution on combination therapies.

(HealthDay)—It's OK for some patients with asthma to stick with a combination of medications instead of abandoning one because of concerns about complications, a new analysis of existing research suggests.

The U.S. has warned that who take both long-acting beta-agonist and inhaled corticosteroid medications should be cautious about using them together once their condition is under control.

Long-acting beta-agonists—such as drugs known by the Serevent, Foradil and Brovana—could cause side effects, the FDA cautioned, as could combination drugs. For that reason, the agency suggested that consider going with inhaled corticosteroids alone.

However, the new analysis came to a different conclusion. "Adding a long-acting beta-agonist to an inhaled corticosteroid medication makes a lot of sense in a number of patients since you get better control of the disease," said Dr. Thomas Casale, chief of allergy and immunology at Creighton University, and lead author of the report.

The report was published online Aug. 27 in the journal .

At issue is how to best treat adults and older children who suffer from moderate to severe asthma.

Inhaled corticosteroids, which come in inhalers and are known by brand names such as Azmacort and Flovent, are often prescribed by themselves to reduce wheezing and other symptoms. They're usually taken daily but don't relieve asthma attacks when they're occurring. (Short-acting beta-agonists, such as the drug , treat asthma attacks themselves.)

The newer long-acting beta-agonists are frequently used with . Some medications, sold under the brand names Symbicort and Advair, combine both types of drugs.

This latest analysis, which examined five studies involving patients aged 15 or older, found that removing a long-acting beta-agonist—but continuing treatment with an inhaled corticosteroid—was worse for patients than continuing both drugs.

Patients who dropped the long-acting beta-agonists reported more asthma problems and fewer days with no symptoms. The findings also suggested that these patients needed more treatment of . The studies, however, didn't allow researchers to examine the risk of death under the different approaches.

Casale said he doesn't think the FDA's concerns about death and other health problems—which resulted in a bold warning on drug labels— have deterred physicians from prescribing the combination treatments. However, he said, they have reinforced guidelines recommending against using the long-acting beta-agonists as treatments by themselves.

"I think all of us agree with that," he said. "They're only to be used in conjunction with an inhaled corticosteroid, and only in those who aren't adequately controlled."

In an accompanying journal editorial, Dr. Chee Chan and Dr. Andrew Shorr, both from the division of pulmonary and critical care medicine at Washington Hospital Center in Washington D.C., wrote that they hoped the analysis "helps to lift some of the black clouds" in the debate over the use of the asthma drugs.

More information: For more about asthma, visit the U.S. National Library of Medicine.

Journal reference: JAMA Internal Medicine search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Stem-cell-based strategy boosts immune system in mice

Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...

Immunology created May 16, 2013 | popularity 4.8 / 5 (5) | comments 0 | with audio podcast

Resistance to visceral leishmaniasis: New mechanisms involved

Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...

Immunology created May 16, 2013 | popularity not rated yet | comments 0

Women's immune systems remain younger for longer

Women's immune systems age more slowly than men's, suggests research in BioMed Central's open access journal Immunity & Ageing. The slower decline in a woman's immune system may contribute to women living longer than men. ...

Immunology created May 14, 2013 | popularity not rated yet | comments 0

Newly described type of immune cell and T cells share similar path to maturity, according to new study

(Medical Xpress)—Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that ...

Immunology created May 14, 2013 | popularity 5 / 5 (3) | comments 0 | with audio podcast

Not all cytokine-producing cells start out the same way, study finds

(Medical Xpress)—Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory ...

Immunology created May 13, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

Alzheimer's leaves bilingual victims stranded in Canada

The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.